Richter's Transformation

October 23, 2024

Designing Research Trials for Richter’s Transformation

Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.

October 11, 2024

Epcoritamab Gives Deep Response in Richter’s Transformation

Epcoritamab, a bispecific antibody, led to a 50% overall and 35% complete response rate in all Richter’s transformation patients.

August 8, 2024

Triple Combination Therapy for Richter’s Transformation

For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.

August 8, 2024

Tislelizumab Plus Zanubrutinib for Richter’s Transformation

The combination therapy of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation.

May 31, 2024

Incidence of Richter’s Transformation in the Targeted Therapy Era

While the incidence of Richter’s transformation has not changed dramatically with the introduction of targeted therapies, those who received CLL / SLL treatment in the targeted therapy era appear to have a lower risk of Richter’s transformation.

March 5, 2024

Pirtobrutinib for Richter’s Transformation

Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.

November 14, 2023

Biology and Genetics of Richter’s Transformation

This was a very complex basic science presentation from iwCLL 2023 by Erin Parry, MD. Ph.D. of Dana Farber Cancer Institute in Boston, MA on the evolution of CLL (chronic lymphocytic leukemia) to Richter’s transformation (RT),

November 14, 2023

Glofitamab for Richter’s Transformation Gives Durable Remission

Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.

October 18, 2023

Venetoclax, Atezolizumab, and Obinutuzumab Combination Therapy for Richter’s Syndrome – ICML 2023

Atezolizumab, obinutuzumab, and venetoclax combination therapy is active in patients with untreated DLBCL-Richter’s Syndrome (RS).

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Richter’s Transformation

Designing Research Trials for Richter’s Transformation

Epcoritamab Gives Deep Response in Richter’s Transformation

Triple Combination Therapy for Richter’s Transformation

Tislelizumab Plus Zanubrutinib for Richter’s Transformation

Incidence of Richter’s Transformation in the Targeted Therapy Era

Pirtobrutinib for Richter’s Transformation

Biology and Genetics of Richter’s Transformation

Glofitamab for Richter’s Transformation Gives Durable Remission

Venetoclax, Atezolizumab, and Obinutuzumab Combination Therapy for Richter’s Syndrome – ICML 2023

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT